Idiopathic thrombocytopenic purpura and percutaneous coronary stenting: A dangerous duo?

Idiopathic thrombocytopenic purpura and coronary artery disease: comparison between coronary artery bypass grafting and percutaneous coronary intervention

“…From 1999 to January 2010, 15 cases of patients affected by ITP who underwent PCI were reported ( Table 2) [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39].…”

“…Generally, a bare metal stent (BMS) was implanted during PCI. Drug-eluting stent (DES) implantation was reported for two patients [33,35], Angioplasty without stent implantation was completed in two cases [29,34], but in one case it led to rapid in-stent re-stenosis needing stent implantation [29]. Glycoprotein (GP) IIb/IIIa inhibitors were not used.…”

Coronary artery stenting in a patient with chronic immune thrombocytopenic purpura: a clinical conundrum

“…However, using drug-eluting stents would still require our patient to be on dual-antiplatelets therapy for at least a year, exposing him to a higher bleeding risk. Moretti et al 9 reported a case in which coronary stenting with drug-eluting stents was done successfully with dual antiplatelet agents for 6 months without any stent thrombosis. However, the severity of thrombocytopenia was mild with a platelet count of 110000µl at baseline compared with our patient.…”

Immunthrombozytopenie - Onkopedia-Leitlinien Update: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH + SSH und GPOH

“…Antikoagulanzien sind bei Thrombozytopenie in der Regel kontraindiziert. Für diese klinisch immer häufigeren Situationen gibt es nur Fallberichte, die keine evidenzbasierte Empfehlung erlauben [78,79,80,81]. …”